Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA rat study tied one of the worst face pains to a deep brainstem nucleus running a CGRP-RAMP1-PKA signal, the same peptide target migraine drugs block. Silencing the nucleus or blocking the receptor eased the pain, but this is a one-lab mechanism study, not a therapy.
A network meta-analysis of 58 randomised trials and 24,214 people without diabetes found the newer multi-target drugs (retatrutide, tirzepatide, CagriSema) beat the conventional GLP-1 shots. The hierarchy is probabilistic, though, and one of the most effective drugs was also among the hardest to stay on.
A retrospective look at 23 adults with cystic-fibrosis-related diabetes found lung function rose a median 6 points over six months on a GLP-1 drug, and the gain held after adjusting for weight loss. Small, uncontrolled, and a reason to run the trial, not to conclude.
A randomized, double-blind crossover pushed oxytocin in healthy men to twice its natural peak during a graded glucose challenge. C-peptide, glucagon, GIP, GLP-1, and both bone-turnover markers stayed level with placebo. A clean null on a hormone the hype had cast as a quiet metabolic regulator.
A TriNetX study of 56,142 matched pairs found that women over 50 who already had osteoporosis had about half as many collapsed vertebrae (1.9 versus 4.3 percent) and half as many spine surgeries if they took a GLP-1 drug. It is observational, and a relative risk of 0.43 is large enough that healthier patients, not the drug, may explain part of it.
A prospective randomized trial in 174 men with prostate cancer put leuprolide and goserelin head-to-head for a year. Both peptides shut testosterone and PSA down about equally, but the costs diverged: leuprolide brought the sharpest PSA drop along with hot flashes in 90 percent of men and more weight gain, while goserelin ran less steadily and carried more cardiovascular trouble. The takeaway is that two generic LHRH agonists with the same mechanism are not the same clinical decision.
The first study to line up the acid-reflux question across the United States, Japan, and Canada found that heartburn shows up in reports about GLP-1 drugs two to five times more often than in reports about an older diabetes pill, strongest for semaglutide and inverted for exenatide. But a reporting signal counts paperwork, not patients: nobody measured how many people actually got reflux, and the most talked-about medicines on earth generate more reports of everything.
A TriNetX study of 69,222 diabetics found GLP-1 users progressed to trigger-finger surgery slightly less often than matched non-users. There was no difference at six months, and the two-year gap was 1.5 percentage points.
A meta-analysis of 78 observational studies found GLP-1 users developed fewer of ten obesity-linked cancers, with the sharpest numbers coming from comparisons against insulin. Every one of the 78 studies was observational, and the comparator itself marks sicker patients.
A network meta-analysis of 15 studies and 1,877 people ranked GLP-1 drugs first for lowering the apnea-hypopnea index (15.28 fewer breathing events an hour) in overweight patients with sleep apnea. Their improvement in daytime sleepiness was statistically real but ten times below the threshold a patient would notice, and plain aerobic exercise ranked first on that symptom. No comparison earned a high-certainty rating.
A real-world study of 52 children on vosoritide across six Latin American countries (EVOLAC) found height Z-scores climbed more than a full standard deviation over three years, with high adherence and mild side effects. Body proportions stayed flat, there was no control arm, and the surrogate the drug was approved on, growth velocity, is not the skull-base, spinal, or sleep-apnea complications that make achondroplasia dangerous.
Rusfertide (MIMRYLO) imitates hepcidin, the body's iron-traffic hormone, starving overactive marrow of the iron it needs to build red cells. In the 293-patient VERIFY trial it cut the need for bloodletting and held hematocrit down. The endpoint is disease burden, not the clots and cancers that make the disease dangerous.
In a first-in-human phase Ib trial, a patient's own red blood cells were coated with seven myelin fragments and reinfused. Three months later the immune signature had shifted toward tolerance, with regulatory T cells up and a nerve-damage marker down. Nine patients, no control arm, a single dose.
Injected into the spinal fluid of burned mice, semaglutide relieved pain not by acting directly but by pushing spinal astrocytes to release enkephalins, the body's homemade opioids, at the delta-opioid receptor. It is a mouse study, and the drug's usual under-the-skin route was not tested.
An umbrella review found ten meta-analyses tying GLP-1 drugs to lower atrial fibrillation, but they re-pool the same trials. Two built from an identical six studies still reported different results (hazard ratios 0.58 and 0.78), and quality was rated low to critically low across the board.